Respiratory transmission of mpox remains biologically plausible, but human evidence is thin
The respiratory route has long occupied an uneasy middle ground in discussions of mpox transmission. Laboratory work, animal challenge studies, and environmental sampling all keep the possibility alive, yet real-world outbreak data still point most strongly toward close contact as the dominant driver of spread. A review in The Lancet Microbe pulls those threads together and arrives at a restrained conclusion: human-to-human respiratory transmission appears low, even if it cannot be ruled out outright.
The question matters because transmission route shapes everything that follows at the bedside and in public health practice. If virus dispersal through the air were common, the infection-control burden would look very different, with broader implications for isolation, ventilation, personal protective equipment, and exposure tracing. Instead, the current evidence suggests a narrower pathway, one that fits better with skin-to-skin contact and other forms of close, prolonged interaction than with routine airborne spread.
Animal studies support a respiratory route, but they do not define human risk
Experimental infection studies have shown that MPXV can initiate infection in animals through respiratory routes. In controlled settings, animal-to-animal respiratory transmission has also been demonstrated. Those findings establish biological plausibility. They show the virus is capable of entering through the respiratory tract under the right conditions, and that the upper airway cannot be dismissed as an irrelevant portal of entry.
Even so, animal data rarely map neatly onto community transmission. Dose, exposure duration, host susceptibility, and confinement conditions all differ sharply from everyday human encounters. A caged laboratory system can magnify transmission pathways that may be inefficient in open, variable human settings. The respiratory route may therefore be possible without being epidemiologically dominant.
Environmental detection does not equal efficient spread between people
Airborne environmental studies have detected MPXV in sampled settings. That finding is important, but it has a limited interpretive ceiling. Detection of viral material in air or on environmental surfaces shows that virus can be present in the surrounding space; it does not prove that enough viable virus is traveling through air to drive repeated person-to-person transmission.
This distinction is central. Molecular detection can capture fragments, contamination, or transient aerosolization without establishing a clinically meaningful chain of infection. In respiratory transmission research, the leap from presence to causation is large, and the review treats that gap carefully. The available environmental evidence raises a signal, but it does not convert suspicion into proof.
Outbreak investigations still point most strongly to close contact
Real-life outbreak data carry the greatest weight for estimating how mpox spreads in human populations. Across reported outbreaks, transmission has been associated with close contact. That pattern is consistent with the characteristic clinical presentation of mpox, where lesions and direct exposure create obvious opportunities for spread.
Here the epidemiologic logic is straightforward. When the virus is repeatedly linked to intimate, prolonged, or physical contact, the respiratory pathway becomes harder to isolate as the primary mechanism. Case reports can be tempting places to search for aerosol transmission, but route assignment in individual infections is notoriously difficult. A person may have had multiple exposures, some remembered and some not, and the true route often remains inferential rather than demonstrable.
No specific case reports have so far pinned transmission on the respiratory route alone. That absence does not eliminate the possibility, but it does constrain the strength of the claim. In a literature built from outbreaks, clusters, and environmental observations, the burden of proof remains high for calling respiratory spread a major driver.
Why the airway still cannot be ignored
A low likelihood is not the same as no likelihood. MPXV can infect through respiratory routes in experimental systems, and airborne sampling has detected the virus in relevant settings. Those findings are enough to justify continued study, especially in contexts where patients generate aerosols, where ventilation is poor, or where close contact is prolonged and layered with other exposures.
Respiratory spread could also matter in narrowly defined circumstances rather than as the usual mode of transmission. That possibility is especially relevant for infection prevention in hospitals, where clinicians often have to act before the full exposure history is known. Even a low-probability route can influence triage, isolation, and worker protection when the consequences of missed transmission are substantial.
The present evidence favors restraint, not complacency
The review’s main message is not that respiratory spread is impossible. It is that the balance of evidence does not support respiratory transmission as the dominant explanation for human mpox spread. The current data hierarchy places the strongest weight on close contact, while animal experiments and environmental detections occupy a supporting role that keeps the question open.
One sentence captures the state of affairs plainly: the human respiratory transmission signal remains weak.
That assessment has practical value. Infection-control policies should not be built around worst-case assumptions when the epidemiology repeatedly points elsewhere. At the same time, surveillance should not close the door on a route that remains biologically plausible and experimentally demonstrable. The safest reading is also the most disciplined one: use the strongest human evidence as the anchor, and continue to test the respiratory hypothesis where it can be meaningfully examined.
What future studies still need to separate
Several questions remain unresolved. Better work is needed to distinguish contamination from viable airborne virus, and to separate true respiratory acquisition from the close-contact exposures that often accompany mpox cases. Human studies will need sharper exposure reconstruction, stronger virologic methods, and enough detail to determine whether airborne material can actually sustain infection between people under ordinary conditions.
For now, the available evidence supports a cautious clinical stance. MPXV respiratory transmission may be possible, but the probability of routine human-to-human spread by that route appears low. The open question is not whether the airway can be involved under experimental conditions; it is whether it meaningfully drives transmission in everyday human outbreaks, and current evidence has not shown that to be the case.